SARS-CoV-2 Main Protease Inhibitors for Mutation Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds and methods to treat viral infections, particularly those caused by coronaviruses, which mutate easily and can spread between animals and humans, leading to infectious-disease outbreaks.
Innovation Solution
Development of a compound formula (I) and its pharmaceutically acceptable salts, where ring A is C6-10 aryl or 5- to 10-membered heteroaryl, with specific substituents and linkages, designed to inhibit SARS-CoV-2 main protease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral treatments are used, then existing viral infections can be treated, but they are ineffective against mutating coronaviruses and new variants
Solution Approach 1:
The patent employs parameter changes by systematically varying the chemical structure of the inhibitor compounds (Formula I), including different aryl/heteroaryl rings, substituent groups (R1, R1a, R1b), linkers (L1, L2, L3), and heteroatoms (X1-X7). This structural diversification allows the compounds to maintain binding affinity to the conserved main protease active site while adapting to viral mutations, thereby simultaneously improving reliability and adaptability.
2Adaptability or versatility
If broad-spectrum antiviral compounds are developed, then they can treat multiple viral infections, but the complexity of compound design and synthesis increases
Solution Approach 1:
The inhibitor compound is segmented into distinct functional modules: a core aryl/heteroaryl ring system (ring A), multiple substituent positions (R1, R1a, R1b) that can be independently optimized, flexible linker regions (L1, L2, L3), and terminal heterocyclic groups (ring B). This segmentation allows medicinal chemists to systematically modify individual modules to achieve broad-spectrum activity while managing synthesis complexity through modular assembly.
Solution Approach 2:
The patent designs a universal scaffold (Formula I) with multiple points of chemical modification that can generate a series of analogs active against different coronavirus variants and potentially other coronaviruses. The conserved main protease structure across coronavirus species allows this multi-functional platform to target a common essential enzyme, achieving broad-spectrum utility without requiring completely different molecular architectures for each virus.
3Reliability
If highly specific inhibitors targeting conserved regions are designed, then they can resist viral mutations, but the selectivity for targeting specific viral enzymes over host enzymes decreases
Solution Approach 1:
The patent applies local quality by designing specific interactions between the inhibitor and the main protease active site. The compound features localized functional groups (heteroatoms X1-X7, carbonyl groups, aromatic rings) that form specific hydrogen bonds, hydrophobic interactions, and pi-stacking with amino acid residues in the protease binding pocket. These localized interactions provide both mutation resistance (by targeting conserved catalytic residues) and selectivity (by exploiting unique structural features of the viral protease compared to host proteases).
Data Source
AI summary
The present disclosure relates to compounds of Formula I:and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.